PD Latest Research

Newsfeed:

  • Malignant syndromes: current advances
    Expert Opin Drug Saf. 2021 Apr 17. doi: 10.1080/14740338.2021.1919622. Online ahead of print.ABSTRACTINTRODUCTION: Many drugs are known to induce malignant syndromes. The most common malignant syndromes are induced by the use of antipsychotics and anesthetics and the withdrawal of anti-Parkinson drugs. As the clinical manifestations of antipsychotic malignant syndrome, Parkinson's disease hyperpyrexia syndrome and anesthetic-induced malignant syndrome are very similar, ... read more
    Source: PubMedPublished on 2021-04-19By Minghua Tao
  • Cost-effectiveness of opicapone and entacapone in reducing off-time in Parkinson’s Disease patients treated with levodopa/carbidopa
    J Med Econ. 2021 Apr 18:1. doi: 10.1080/13696998.2021.1916750. Online ahead of print.ABSTRACTAIMS: To assess from a US payer perspective the relative cost-effectiveness of the catechol-O-methyltransferase inhibitors opicapone and entacapone when used adjunctively to levodopa/carbidopa (LD/CD) in patients with Parkinson's disease (PD), based on the drugs' effects to reduce absolute OFF-time hours in PD patients.MATERIALS AND METHODS: A Markov model was ... read more
    Source: PubMedPublished on 2021-04-19By Ryan N Hansen
  • Biophysical characterization of local field potential recordings from directional deep brain stimulation electrodes
    Clin Neurophysiol. 2021 Mar 10:S1388-2457(21)00076-6. doi: 10.1016/j.clinph.2021.01.027. Online ahead of print.ABSTRACTOBJECTIVE: Two major advances in clinical deep brain stimulation (DBS) technology have been the introduction of local field potential (LFP) recording capabilities, and the deployment of directional DBS electrodes. However, these two technologies are not operationally integrated within current clinical DBS devices. Therefore, we evaluated the theoretical advantages of using ... read more
    Source: PubMedPublished on 2021-04-19By M Sohail Noor
  • Late life psychotic features in prodromal Parkinson’s disease
    Parkinsonism Relat Disord. 2021 Apr 7;86:67-73. doi: 10.1016/j.parkreldis.2021.04.001. Online ahead of print.ABSTRACTINTRODUCTION: Some case series have suggested that psychotic features could occur even before the onset of motor symptoms of Parkinson's Disease (PD). Our aim was to investigate a possible association between psychotic symptoms and prodromal Parkinson's disease in a population-based cohort, the Hellenic Longitudinal Investigation of Aging and Diet ... read more
    Source: PubMedPublished on 2021-04-18By Ioanna Pachi
  • Natural history of lung function over one year in patients with Parkinson’s disease
    Respir Med. 2021 Apr 15;182:106396. doi: 10.1016/j.rmed.2021.106396. Online ahead of print.ABSTRACTBACKGROUND: Little is known about decline in lung function in Parkinson's disease (PD). To assess these changes, we assessed the changes in lung function that occurred over 12 months in patients on standard PD therapy as part of the observational cohort of an open-label study of inhaled levodopa (CVT-301) in ... read more
    Source: PubMedPublished on 2021-04-18By David A Kaminsky
  • Mucus plugging on computed tomography and chronic bronchitis in chronic obstructive pulmonary disease
    Respir Res. 2021 Apr 17;22(1):110. doi: 10.1186/s12931-021-01712-0.NO ABSTRACTPMID:33865371 | DOI:10.1186/s12931-021-01712-0 ... read more
    Source: PubMedPublished on 2021-04-18By Victor Kim
  • Serum tyrosine is associated with better cognition in lewy body dementia
    Brain Res. 2021 Apr 15:147481. doi: 10.1016/j.brainres.2021.147481. Online ahead of print.ABSTRACTAmino acids' neuroactivity, and roles in excitotoxity and oxidative stress are linked to dementia. We aimed to investigate whether circulating amino acid concentrations were associated with cognitive decline in patients with mild Alzheimer's disease (AD) and Lewy body dementia (LBD). Baseline serum amino acid concentrations were measured in 89 patients ... read more
    Source: PubMedPublished on 2021-04-18By McCann Adrian
  • alpha-syn and SNP rs356219 as a potential biomarker in blood for Parkinson’s disease in Mexican Mestizos
    Neurosci Lett. 2021 Apr 15:135901. doi: 10.1016/j.neulet.2021.135901. Online ahead of print.ABSTRACTClinical criteria diagnose Parkinson's disease (PD), therefore, it is crucial to find biological elements that could support diagnosis or even act as prognostic tools of PD. The SNCA gene codifies a protein called α - synuclein; several studies associate genetic and biochemical factors of SNCA with PD, including transcript and ... read more
    Source: PubMedPublished on 2021-04-18By Alma Cristina Salas-Leal
  • Late life psychotic features in prodromal Parkinson’s disease
    Parkinsonism Relat Disord. 2021 Apr 7;86:67-73. doi: 10.1016/j.parkreldis.2021.04.001. Online ahead of print.ABSTRACTINTRODUCTION: Some case series have suggested that psychotic features could occur even before the onset of motor symptoms of Parkinson's Disease (PD). Our aim was to investigate a possible association between psychotic symptoms and prodromal Parkinson's disease in a population-based cohort, the Hellenic Longitudinal Investigation of Aging and Diet ... read more
    Source: PubMedPublished on 2021-04-18By Ioanna Pachi
  • Mucus plugging on computed tomography and chronic bronchitis in chronic obstructive pulmonary disease
    Respir Res. 2021 Apr 17;22(1):110. doi: 10.1186/s12931-021-01712-0.NO ABSTRACTPMID:33865371 | DOI:10.1186/s12931-021-01712-0 ... read more
    Source: PubMedPublished on 2021-04-18By Victor Kim
  • Serum tyrosine is associated with better cognition in lewy body dementia
    Brain Res. 2021 Apr 15:147481. doi: 10.1016/j.brainres.2021.147481. Online ahead of print.ABSTRACTAmino acids' neuroactivity, and roles in excitotoxity and oxidative stress are linked to dementia. We aimed to investigate whether circulating amino acid concentrations were associated with cognitive decline in patients with mild Alzheimer's disease (AD) and Lewy body dementia (LBD). Baseline serum amino acid concentrations were measured in 89 patients ... read more
    Source: PubMedPublished on 2021-04-18By McCann Adrian
  • alpha-syn and SNP rs356219 as a potential biomarker in blood for Parkinson’s disease in Mexican Mestizos
    Neurosci Lett. 2021 Apr 15:135901. doi: 10.1016/j.neulet.2021.135901. Online ahead of print.ABSTRACTClinical criteria diagnose Parkinson's disease (PD), therefore, it is crucial to find biological elements that could support diagnosis or even act as prognostic tools of PD. The SNCA gene codifies a protein called α - synuclein; several studies associate genetic and biochemical factors of SNCA with PD, including transcript and ... read more
    Source: PubMedPublished on 2021-04-18By Alma Cristina Salas-Leal
  • Natural history of lung function over one year in patients with Parkinson’s disease
    Respir Med. 2021 Apr 15;182:106396. doi: 10.1016/j.rmed.2021.106396. Online ahead of print.ABSTRACTBACKGROUND: Little is known about decline in lung function in Parkinson's disease (PD). To assess these changes, we assessed the changes in lung function that occurred over 12 months in patients on standard PD therapy as part of the observational cohort of an open-label study of inhaled levodopa (CVT-301) in ... read more
    Source: PubMedPublished on 2021-04-18By David A Kaminsky
  • Netrin-1 receptor UNC5C cleavage by active delta-secretase enhances neurodegeneration, promoting Alzheimer’s disease pathologies
    Sci Adv. 2021 Apr 16;7(16):eabe4499. doi: 10.1126/sciadv.abe4499. Print 2021 Apr.ABSTRACTNetrin-1, a family member of laminin-related secreted proteins, mediates axon guidance and cell migration during neural development. T835M mutation in netrin receptor UNC5C predisposes to the late-onset Alzheimer's disease (AD) and increases neuronal cell death. However, it remains unclear how this receptor is molecularly regulated in AD. Here, we show that ... read more
    Source: PubMedPublished on 2021-04-17By Guiqin Chen
  • Natural antioxidants in the management of Parkinson’s disease: Review of evidence from cell line and animal models
    J Integr Med. 2021 Mar 27:S2095-4964(21)00035-2. doi: 10.1016/j.joim.2021.03.007. Online ahead of print.ABSTRACTParkinson's disease (PD) is a chronic progressive neurodegenerative disease. It results from the death of dopaminergic neurons. The pathophysiological mechanisms in idiopathic PD include the production of α-synuclein and mitochondrial respiratory function-affecting complex I, caused by reactive oxygen species. Therefore, the use of natural antioxidants in PD may provide ... read more
    Source: PubMedPublished on 2021-04-17By Reem Abdul-Latif
  • Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
    Neurol Ther. 2021 Apr 17. doi: 10.1007/s40120-021-00246-3. Online ahead of print.ABSTRACTINTRODUCTION: Gocovri (amantadine) extended release capsules are approved for treatment of dyskinesia and as a levodopa adjunct for OFF episodes in patients with Parkinson's disease (PD). We report treatment-related effects on non-motor symptoms (NMS) assessed as secondary outcomes in two trials using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale ... read more
    Source: PubMedPublished on 2021-04-17By Shyamal H Mehta
  • Trimetazidine use in Parkinson’s disease: Is it a resolved problem?
    eNeuro. 2021 Apr 14:ENEURO.0452-20.2021. doi: 10.1523/ENEURO.0452-20.2021. Online ahead of print.ABSTRACTTrimetazidine, an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson's disease (PD). We investigated the impact of this recommendation on the observed trend of trimetazidine use in PD in Hungary from 2010 to 2016 by ... read more
    Source: PubMedPublished on 2021-04-17By Dávid Pintér
  • Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases
    Biomed Pharmacother. 2021 Apr 14;139:111551. doi: 10.1016/j.biopha.2021.111551. Online ahead of print.ABSTRACTThe central nervous system (CNS) is a vital part of the human nervous system, and the incidence of CNS disease is increasing year by year, which has become a major public health problem and a prominent social problem. At present, the drugs most commonly used in the clinic are receptor ... read more
    Source: PubMedPublished on 2021-04-17By Xue Bai
  • Unraveling the mechanisms underlying irregularities in inspiratory rhythm generation in a mouse model of Parkinson’s disease
    J Neurosci. 2021 Apr 14:JN-RM-2114-20. doi: 10.1523/JNEUROSCI.2114-20.2021. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder anatomically characterized by a progressive loss of dopaminergic neurons in the substantia nigra compacta (SNpc). Much less known, yet clinically very important, are the detrimental effects on breathing associated with this disease. Consistent with the human pathophysiology, the 6-hydroxydopamine (6-OHDA) rodent model of ... read more
    Source: PubMedPublished on 2021-04-17By Luiz M Oliveira
  • Structural MRI substrate of long-duration response to levodopa in Parkinson’s disease: an exploratory study
    J Neurol. 2021 Apr 17. doi: 10.1007/s00415-021-10550-5. Online ahead of print.ABSTRACTOBJECTIVE: The long-duration response (LDR) to L-dopa is a sustained benefit deriving from chronic administration of therapy to patients with Parkinson's disease (PD). Almost all patients with early PD may develop the LDR to L-dopa, even if some patients could not at given dosages of the drug. Aim of this ... read more
    Source: PubMedPublished on 2021-04-17By Giulia Donzuso
  • Electrogastrography for diagnosis of early-stage Parkinson’s disease
    Parkinsonism Relat Disord. 2021 Mar 28;86:61-66. doi: 10.1016/j.parkreldis.2021.03.016. Online ahead of print.ABSTRACTINTRODUCTION: Patients with Parkinson's disease (PD) often present with gastric symptoms. Electrogastrography (EGG) can noninvasively assess gastric electric activity and may be useful for early PD diagnosis. The present study aimed to compare the efficacy of EGG in early PD diagnosis with those of 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy and ... read more
    Source: PubMedPublished on 2021-04-17By Nobuyuki Araki
  • Natural antioxidants in the management of Parkinson’s disease: Review of evidence from cell line and animal models
    J Integr Med. 2021 Mar 27:S2095-4964(21)00035-2. doi: 10.1016/j.joim.2021.03.007. Online ahead of print.ABSTRACTParkinson's disease (PD) is a chronic progressive neurodegenerative disease. It results from the death of dopaminergic neurons. The pathophysiological mechanisms in idiopathic PD include the production of α-synuclein and mitochondrial respiratory function-affecting complex I, caused by reactive oxygen species. Therefore, the use of natural antioxidants in PD may provide ... read more
    Source: PubMedPublished on 2021-04-17By Reem Abdul-Latif
  • Trimetazidine use in Parkinson’s disease: Is it a resolved problem?
    eNeuro. 2021 Apr 14:ENEURO.0452-20.2021. doi: 10.1523/ENEURO.0452-20.2021. Online ahead of print.ABSTRACTTrimetazidine, an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson's disease (PD). We investigated the impact of this recommendation on the observed trend of trimetazidine use in PD in Hungary from 2010 to 2016 by ... read more
    Source: PubMedPublished on 2021-04-17By Dávid Pintér
  • Pharmacokinetics of Opicapone and Its Metabolites in Healthy White and Chinese Subjects
    Clin Pharmacol Drug Dev. 2021 Apr 17. doi: 10.1002/cpdd.922. Online ahead of print.ABSTRACTOpicapone (OPC) is a third-generation catechol-O-methyltransferase inhibitor developed to treat Parkinson disease and motor fluctuations. This open-label, single-center, phase 1 study aimed to evaluate the pharmacokinetics (PK) of OPC and its metabolites when administered as single and multiple doses in healthy White and Chinese subjects. The study enrolled ... read more
    Source: PubMedPublished on 2021-04-17By Wei Xue
  • Natural antioxidants in the management of Parkinson’s disease: Review of evidence from cell line and animal models
    J Integr Med. 2021 Mar 27:S2095-4964(21)00035-2. doi: 10.1016/j.joim.2021.03.007. Online ahead of print.ABSTRACTParkinson's disease (PD) is a chronic progressive neurodegenerative disease. It results from the death of dopaminergic neurons. The pathophysiological mechanisms in idiopathic PD include the production of α-synuclein and mitochondrial respiratory function-affecting complex I, caused by reactive oxygen species. Therefore, the use of natural antioxidants in PD may provide ... read more
    Source: PubMedPublished on 2021-04-17By Reem Abdul-Latif
1 2 3 447